The Merck pill, which doesn’t affect protease but instead introduces mutational errors through an enzyme called polymerase, initially showed a 50% reduction in hospitalization and death in high-risk unvaccinated people with mild or moderate COVID-19. ![]() ![]() The Pfizer drug’s effectiveness appears to be a significant improvement over the anti-COVID pill from Merck and Ridgeback Biotherapeutics. “We’re in very advanced regulatory dialogues with both Europe and the U.K., and we have dialogues with most of the major regulatory agencies globally,” Dolsten said in an interview. Pfizer’s chief scientific officer, Mikael Dolsten, said he expects it to be authorized for high-risk patients soon, and that it may not need an FDA advisory panel meeting. Food and Drug Administration (FDA) where it will need to be approved before it becomes available to the public. The company said they sent their final data to the U.S. A course of the drug is 30 pills over five days, some of which are Paxlovid and some of which are an antiviral called ritonavir, which helps keep Paxlovid working in the body for longer. ![]() But the Pfizer drug is meant to work by inhibiting the virus’s ability to break into smaller pieces and replicate itself by dulling an enzyme called protease-not by battling spike proteins.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |